@文章{信息:doi/10.2196/37368，作者="Lamaj, Ganimete和Pablo-Trinidad, Alberto和Butterworth, Ian和Bell, Nolan和Benasutti, Ryan和Bourquard, Aurelien和Sanchez-Ferro, Alvaro和Castro-Gonzalez, Carlos和Jim{\'e} ez- ubieto, Ana和Baumann, Tycho和Rodriguez-Izquierdo, Antonia和Pottier, Elizabeth和Shelton, Anthony和Martinez-Lopez, Joaquin和Sloan, John Mark"，标题=“一种用于癌症化疗患者的无创伤中性粒细胞减少筛查装置(PointCheck)的可用性评估:混合方法观察研究”，期刊=“J Med Internet Res”，年=“2022”，月=“8”，日=“9”，卷=“24”，数=“8”，页=“e37368”，关键词=“数字健康;可用性;以病人为中心的护理;远程监控;决策支持系统;白细胞;诊断;医疗设备;癌症; chemotherapy; infection; white blood cell; technology", abstract="Background: Patients with cancer undergoing cytotoxic chemotherapy face an elevated risk of developing serious infection as a consequence of their treatment, which lowers their white blood cell count and, more specifically, their absolute neutrophil count. This condition is known as neutropenia. Neutropenia accompanied by a fever is referred to as febrile neutropenia, a common side effect of chemotherapy with a high mortality rate. The timely detection of severe neutropenia (<500 absolute neutrophil count/$\mu$L) is critical in detecting and managing febrile neutropenia. Current methods rely on blood draws, which limit them to clinical settings and do not allow frequent or portable monitoring. In this study, we demonstrated the usability of PointCheck, a noninvasive device for neutropenia screening, in a simulated home environment without clinical supervision. PointCheck automatically performs microscopy through the skin of the finger to image the blood flowing through superficial microcapillaries and enables the remote monitoring of neutropenia status, without requiring venipuncture. Objective: This study aimed to evaluate the usability of PointCheck, a noninvasive optical technology for screening severe neutropenia, with the goal of identifying potential user interface, functionality, and design issues from the perspective of untrained users. Methods: We conducted a multicenter study using quantitative and qualitative approaches to evaluate the usability of PointCheck across 154 untrained participants. We used a mixed method approach to gather usability data through user testing observations, a short-answer qualitative questionnaire, and a standardized quantitative System Usability Scale (SUS) survey to assess perceived usability and satisfaction. Results: Of the 154 participants, we found that 108 (70.1{\%}) scored above 80.8 on the SUS across all sites, with a mean SUS score of 86.1 across all sites. Furthermore, the SUS results indicated that, out of the 151 users who completed the SUS survey, 145 (96{\%}) found that they learned how to use PointCheck very quickly, and 141 (93.4{\%}) felt very confident when using the device. Conclusions: We have shown that PointCheck, a novel technology for noninvasive, home-based neutropenia detection, can be safely and effectively operated by first-time users. In a simulated home environment, these users found it easy to use, with a mean SUS score of 86.1, indicating an excellent perception of usability and placing this device within the top tenth percentile of systems evaluated for usability by the SUS. Trial Registration: ClinicalTrials.gov NCT04448314; https://clinicaltrials.gov/ct2/show/NCT04448314 (Hospital Universitario 12 de Octubre registration) and NCT04448301; https://clinicaltrials.gov/ct2/show/NCT04448301 (Boston Medical Center registration) ", issn="1438-8871", doi="10.2196/37368", url="//www.mybigtv.com/2022/8/e37368", url="https://doi.org/10.2196/37368", url="http://www.ncbi.nlm.nih.gov/pubmed/35943786" }